Following publication, concerns were raised regarding the validity of the data in the article. Following investigation, which was conducted in accordance with Frontiers’ policies, the Chief Editor concluded that the article’s conclusions and assertions were not sufficiently supported by the findings from the material provided; therefore, the article has been retracted. This retraction was approved by the Chief Editors of Frontiers in Oncology.
The authors did not agree with the retraction.
Summary
Keywords
ZNF655, Glioma, prognosis, phenotype, tumorigenesis, AURKA
Citation
Frontiers Editorial Office (2023) Retraction: ZNF655 promotes the progression of glioma through transcriptional regulation of AURKA. Front. Oncol. 13:1294900. doi: 10.3389/fonc.2023.1294900
Received
15 September 2023
Accepted
22 September 2023
Published
30 October 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2023
Updates
Copyright
© 2023 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.